Allogeneic stem cell transplantation in second complete remission
- Slides: 6
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Kazimierz Halaburda, Myriam Labopin, Audrey Mailhol, Gerard Socié, Charles Craddock, Mahmoud Aljurf, Dietrich Beelen, Jan J. Cornelissen, Jean-Henri Bourhis, Hélène Labussière-Wallet, Didier Blaise, Tobias Gedde-Dahl, Maria Gilleece, Ibrahim Yakoub-Agha, Ghulam Mufti, Jordi Esteve, Mohamad Mohty, and Arnon Nagler haematol Volume 105(6): 1723 -1730 June 1, 2020 © 2020 by Ferrata Storti Foundation
Patients’ and transplant characteristics. Kazimierz Halaburda et al. Haematologica 2020; 105: 17231730 © 2020 by Ferrata Storti Foundation
Leukemia-free survival (LFS), overall survival (OS), and relapse incidence (RI) in patients with core-binding factor acute myeloid leukemia (CBF AML) transplanted in second complete remission for patients with inv(16) versus t(8; 21). 2 -year probability of L. . . Kazimierz Halaburda et al. Haematologica 2020; 105: 17231730 © 2020 by Ferrata Storti Foundation
Leukemia-free survival (LFS), overall survival (OS), and relapse incidence (RI) in patients with core-binding factor acute myeloid leukemia in patients without versus with molecular remission pre-transplant. 2 -year probability of LFS: 49% (95%CI: 39. 8 -58. 2). . . Kazimierz Halaburda et al. Haematologica 2020; 105: 17231730 © 2020 by Ferrata Storti Foundation
Multivariate analysis using Cox proportional hazards model. Kazimierz Halaburda et al. Haematologica 2020; 105: 17231730 © 2020 by Ferrata Storti Foundation
Mortality during follow up. Kazimierz Halaburda et al. Haematologica 2020; 105: 17231730 © 2020 by Ferrata Storti Foundation
